Korean Journal of Chemical Engineering, Vol.32, No.4, 576-582, April, 2015
Effect of an ionic liquid on vancomycin crystallization
E-mail:
We first developed a vancomycin crystallization process using an ionic liquid (IL) and improved the crystallization efficiency by optimization of crystallization conditions (pH, conductivity, solution of distilled water and IL/acetone ratio, crystallization temperature, IL concentration). We also investigated the effect of major process parameters on crystallization, using an electron microscope, and identified morphology by XRD analysis. Using ILs (1-butyl-3- methylimidazolium tetrafluoroborate ([BMIm][BF4]), 1-butyl-3-methylimidazolium hexafluorophosphate ([BMIm] [PF6])), vancomycin crystals were successfully formed under the optimal crystallization conditions: pH 4.5; conductivity, 10 mS/cm; solution of distilled water and IL/acetone ratio, 1 : 3.5 (v/v); crystallization temperature, 10 oC; IL concentration, 20% (v/v). When using an IL ([BMIm][BF4]), the time required for crystallization in the existing crystallization methods (~24 hr) was dramatically decreased (~9 hr) and high-quality vancomycin crystals were successfully formed.
- Yan H, Qi D, Cheng X, Song Z, Li W, He B, J. Antibiot., 51, 750 (1998)
- Griffith RS, J. Antimicrob. Chemoter., 14, 1 (1984)
- Kim SI, Han CY, Jung HS, Lee JS, Ok SY, Kim SC, Korean J. Anesthesiol., 51, 727 (2006)
- United States Pharmacopoeia (USP 29), Vancomycin hydrochloride, United State Pharmacopeial Convention, Inc. (2006). (2006)
- Javadzadeh Y, Mohammadi A, Khoei N, Nokhodchi A, Acta Pharmacol. Sin., 59, 187 (2009)
- Kim SI, Jeong KE, Jeong SY, Kim CU, J. Korean Oil Chem. Soc., 25, 232 (2008)
- Kim WS, Lee EK, Korean J. Biotechnol. Bioeng., 20, 164 (2005)
- Kim KJ, Prospect. Ind. Chem., 4(4), 1 (2001)
- Lee JY, Lee KH, Chae HJ, Kim JH, Korean J. Chem. Eng., 27(5), 1538 (2010)
- Kim YN, Lee JY, Kim JH, Process Biochem., 46, 2068 (2011)
- Kwak EA, Kim SJ, Kim JH, Korean J. Chem. Eng., 29(11), 1487 (2012)
- Kroon MC, Toussaint VA, Shariati A, Florusse LJ, Spronsen JV, Witkamp GJ, Peters CJ, Green Chem., 10, 333 (2008)
- Tang B, Bi W, Tian M, Row KH, J. Chromatogr. B, 904, 1 (2012)
- Li XX, Xu XD, Dan YY, Zhang ML, Crystallogr. Rep., 54, 1285 (2009)
- Judge RA, Takahashi S, Longenecker KL, Fry EH, Zapatero CA, Chi ML, Cryst. Growth Des., 9, 3463 (2009)
- Wang Z, Fang W, Li Y, Zhang J, Gu Q, Korean J. Chem. Eng., 31(6), 919 (2014)
- Hebel D, Urdingen M, Hekmat D, Botz DW, Cryst. Growth Des., 13, 2499 (2013)
- Pusey ML, Paley MS, Turner MB, Rogers RD, Cryst. Growth Des., 7, 787 (2007)
- Lee JW, Jung YT, Suh JW, Lee KS, US Patent, 7,018,814 (2006). (2006)
- Food US, Drug Administration, Vancomycin solubility study, Report to office of generic drugs; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm082291.pdf (2008). (2008)
- Claudius JS, Neau SH, Int. J. Pharm., 168, 41 (1998)
- Kim SJ, Kim JH, Korean J. Chem. Eng., 10.1007/s11814-014-0222-0. (2014)
- Freire MG, Santos LMNBF, Fernandes AM, Coutinho JAP, Marrucho IM, Fluid Phase Equilib., 261(1-2), 449 (2007)
- Garcia-Ruiz JM, Gonzalez-Ramirez LA, Gavira JA, Otalora F, Acta Crystallogr. Sect. D-Biol. Crystallogr., 58, 1638 (2002)